RecallRadar

FDA Device recall Z-1677-2015

Alere i Influenza A & B Product Usage: The Alere i Influenza A and B assay, performed on the Alere i Instrument, is a rapid molecular in vi…

On 2015-06-03 the FDA classified a Class II recall of Alere i Influenza A & B Product Usage: The Alere i Influenza A and B assay, performed on the Alere i Instrument, is a rapid molecular in vi… by Alere Scarborough, citing high invalid rate and an increased risk of false negative results with certain lots of the Alere i Influenza A & B kit.

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1677-2015
ClassificationClass II
Statusterminated
Initiated2015-04-22
Published2015-06-03
Last updated2026-09-13 11:53 UTC
CompanyAlere Scarborough
DistributionUS

Product

Alere i Influenza A & B Product Usage: The Alere i Influenza A and B assay, performed on the Alere i Instrument, is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology for the qualitative detection and discrimination of influenza A and B viral RNA in nasal swabs from patients with signs and symptoms of respiratory infection. It is intended for use as an aid in the differential diagnosis of influenza A and B viral infections in humans, in conjunction with clinical and epidemiological risk factors. The assay is not intended to detect the presence of influenza C virus.

Reason

High invalid rate and an increased risk of false negative results with certain lots of the Alere i Influenza A & B kit.

Identifiers

code_infoPN 425-024, LN 0072633 (United States Distribution) and PN 425-000, LN 0073888 (distributed in Hong Kong, Singapore - evaluation use only)

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:53 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1677-2015%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.